Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Oct 2016

Moreno L, Linossi C, Esteban I, Gadea N, Carrasco E, Bonache S, Gutiérrez-Enríquez S, Cruz C, Díez O, Balmaña J

Abstract excerpt

PURPOSE: Originally, BRCA testing was used for risk assessment and prevention strategies for breast and ovarian cancer. Nowadays, BRCA status may influence therapeutic decision making at cancer diagnosis. Our objective was to analyze whether the medical advances have changed the burden and pattern of referral, and the pathogenic mutation detection rate. METHODS: We included 969 probands from our hereditary cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Making

Share to Genetic Counseling

Share to Germ-Line Mutation

Share to Neoplasm Staging

Share to Ovarian Neoplasms

Share to Registries

Source

Identifiers

PMID: 26742938
DOI: 10.1007/s12094-015-1470-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.PMID 26742938Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Genetic testing in women with breast cancer: implications for treatment.Semantic proximity Read ↗

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline VariantsSemantic proximity Read ↗

Hereditary breast cancer: an update on risk assessment and genetic testing in 2015.Semantic proximity Read ↗

BRCA and beyond: a genome-first approach to familial breast cancer risk assessment.Semantic proximity Read ↗

Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling.Semantic proximity Read ↗

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.Semantic proximity Read ↗

Genetic risk assessment in breast and gynecologic malignancies- what's to know in 2024?Semantic proximity Read ↗

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.Semantic proximity Read ↗

Hereditary gynecologic cancers: risk assessment, counseling, testing and management.Semantic proximity Read ↗

Pivotal Role of Genetic Counselors in the Uptake of Germline Genetic Testing in Non-Metastatic Breast Cancer and the Impact of Testing on Surgical Decision Making.Semantic proximity Read ↗

Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.